Veloxis has announced that once-daily Envarsus® XR, an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, demonstrated that a lower dose of once-daily Envarsus® XR in African-American kidney transplant patients is sufficient to achieve therapeutic tacrolimus blood concentrations, compared to twice-daily immediate release tacrolimus.
The U.S. District Court for the District of Columbia has set a briefing schedule that enabled complete briefing in its pending case by 3 March, 2015. Veloxis is seeking an order requiring FDA to grant final approval to Envarsus® XR. While Veloxis currently expects the matter to be resolved by mid-year 2015, it is possible that delays may occur. There can be no assurance that Veloxis will be successful in its action against FDA.
Veloxis is preparing for launch of Envarsus® XR in the US in the second half of 2015, either for the full indication that would include both de novo and conversion kidney transplant patients or for a more narrow initial indication in the conversion setting.
Veloxis reported a net loss of DKK 27.0 million for the first quarter of 2015 compared to a net loss of DKK 20.0 million for the same period in 2014. The reported net loss is in line with expectations and the financial outlook for 2015 is maintained.
For the first quarter of 2015, Veloxis' sales and marketing costs amounted to DKK 9.8 million. Research and development costs amounted to DKK 20.8 million compared to DKK 26.6 million during the same period in 2014.
On 31 March, 2015, Veloxis had cash and cash equivalents of DKK 233.6 million.
Outlook for 2015
Veloxis maintains its 2015 outlook with an operating loss of DKK 200 – 240 million and a net loss of DKK 195 – 235 million for the financial year 2015.
On 31 March 2015, the Company's cash position equaled DKK 233.6 million, and on 31 December 2015, the Company's cash position is expected to be in the range of DKK 55 – 95 million.
Conference call
A conference call will be held tomorrow, 21 May, 2015 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM EDT (New York).
To access the live conference call, please dial one of the following numbers:
+45 32 71 16 60 (Denmark)
+44 (0) 20 3427 1913 (UK)
+1 212 444 0896 (USA)
Access code 7709988
Following the conference call, a recording will be available on the company's website http://www.veloxis.com.
Business update
Envarsus® in kidney transplant patients
Veloxis has conducted two Phase III studies of Envarsus® in kidney transplant recipients as the basis for its development programme for Envarsus® as a once-daily agent for the prophylaxis of organ rejection in kidney transplantation. The first of these studies, the 3001 Study, was a non-inferiority study performed in 326 stable kidney transplant recipients, and was successfully completed in 2011, meeting its primary efficacy and safety endpoints when compared to Prograf® (tacrolimus, Astellas Pharma Inc.). The second study, Study 3002 was a randomized, double-blind, multicenter study that compared once-daily Envarsus® against twice-daily Prograf® in 543 de novo adult kidney transplant patients and met its primary efficacy and primary safety endpoints. The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of Envarsus® compared to Prograf®. The treatment failure rate for Envarsus® was 18.3% compared to 19.6% for Prograf®, and the difference between the treatments was well within the 10% pre-specified non-inferiority margin. The primary safety analyses were the differences between Envarsus® and Prograf® treatment groups at Month 12 (Day 360) with respect to the incidence of adverse events (AEs) and the incidence of predefined potentially clinically significant laboratory measures including: fasting plasma glucose; platelet count; white blood cell (WBC) count; aminotransaminases; total cholesterol; low density lipoprotein (LDL) cholesterol; triglycerides; and estimated glomerular filtration rate (eGFR). In all instances, there were no statistically significant differences between the two treatments. Specifically, renal function was similar between the two groups at 12 months, as was the incidence of malignancy, infections and new onset diabetes during this period. The study had a one-year extension period which produced similar outcomes.
In addition to the pivotal Phase III studies, Veloxis is conducting a series of Phase IIIb/IV studies to further evaluate potential differences in clinical profile provided by Envarsus®' unique PK profile. The first study completed was the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) study of Envarsus® in kidney transplant recipients experiencing drug-induced tremors. The STRATO study was designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily Envarsus® tablets leads to a measurable improvement in tremor. Results from this study demonstrated that patients switched to Envarsus® demonstrated a statistically significant improvement in hand tremors based on improvement in the FTM Tremor rating scale. Additionally, both the patient- and physician-reported global assessments demonstrated significant overall improvements following the switch to Envarsus®.
Additionally, the ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of Envarsus® in kidney transplant recipients is ongoing. The ASERTAA study is designed to compare the pharmacokinetics of Envarsus® given once-daily to immediate-release twice daily tacrolimus capsules (IR-Tac) in stable African-American renal transplant patients. Primary pharmacokinetic results from this study were presented at the American Transplant Congress in Philadelpia on 3 May, 2015. The key outcomes from this study were:
The overall PK differences (increased absorption [p<0.0001], lower peak blood concentrations [p<0.0001], less peak-to-tough fluctuation in blood levels [p<0.0001]) between Envarsus XR and IR-Tac capsules seen previously in studies of kidney transplant recipients were also confirmed in this exclusively African-American patient population.
The optimal conversion ratio for once-daily extended release Envarsus XR was shown to be approximately 20% lower than the total IR-Tac.
Peak tacrolimus concentration (Cmax) was reduced 30% for patients on Envarsus while intra-day fluctuation was reduced 50%.
Envarsus XR's PK parameters were less impacted by CYP3A5 genotype. IR-Tac was more affected by the presence of the *1 allele, driven primarily by the need to increase dose to achieve therapeutic trough levels, which also resulted in an incremental increase in tacrolimus intra-day peak levels.
Conversion of African-American patients from IR-Tac to Envarsus XR was demonstrated to be readily achieved with a reduction in dose of approximately 20% without concern for genotype status.
In addition, the ASTCOFF (A STeady-state Pharmacokinetic Comparison Of all FK-506 Formulations) Phase IIIb study is ongoing. This study looks to examine the pharmacokinetic differences between Envarsus and the other two tacrolimus formulations commercially available, namely Astagraf XL and Prograf. Primary results from this study are anticipated during 2Q 2015.
Envarsus® Regulatory Strategy
On 29 April, 2013 a Marketing Authorization Application (MAA) was submitted by Veloxis to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in transplant patients in the European Union. The MAA submission was based on the favourable results of the Envarsus® Phase III 3001 Study in stable kidney transplant patients and data from an extensive Phase I and II clinical programme and has been accepted for review by the EMA. On 28 July, 2014, it was announced that the European Commission granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU). Veloxis' marketing and distribution partner Chiesi Farmaceutici launched Envarsus in the EU in late 2014, with launches in Germany and the Netherlands, followed by launch in the UK and Denmark in 2015. Additional launches are anticipated for the majority of the major EU countries during 2015, once local requirements
such as pricing negotiations have been completed.
Veloxis submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® XR in the US for the prevention of organ rejection in kidney transplant recipients on 30 December, 2013. On 30 October, 2014 the FDA granted Tentative Approval for Envarsus® XR for the prophylaxis of rejection in kidney transplant patients. FDA stated that the final approval of Envarsus® XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL®, for the treatment of newly transplanted ('de novo') patients. The tentative approval notification received from FDA included agreement with manufacturing post-marketing commitments as previously proposed by Veloxis during NDA review as well as agreement on final labeling for the product. Veloxis disagrees that exclusivity for Astagraf XL®, which was not identified as a listed drug or relied upon to support approval of Envarsus® XR, should require delay in the formal approval of Envarsus® XR. On 16 December, 2014, Veloxis announced that it has filed an action against the FDA, seeking an order requiring FDA to grant final approval to Envarsus® XR. The U.S. District Court for the District of Columbia has set a briefing schedule that enabled complete briefing in this case by 3 March, 2015. Veloxis currently expects the matter to be resolved by mid-year 2015, but it is possible that delays may occur.
Veloxis is preparing for launch of Envarsus® XR in the US in the second half of 2015, either for the full indication in kidney transplant recipients that would include both de novo and conversion patients or for a more narrow initial indication in the conversion setting.
Revenue
For the first quarter of 2015 Veloxis recognized revenue of DKK 4.3 million compared to DKK 12.2 million in the same period of 2014. Revenue in 2015 consist of commercial sales to Chiesi Farmaceutici S.p.A. and revenue in 2014 consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. Envarsus is currently launched in Germany, Netherlands, UK and Denmark.
Sales and marketing costs
For the first quarter of 2015, Veloxis' sales and marketing costs amounted to DKK 9.8 million compared to DKK 0 million during the same period in 2014. This reflects the building of the marketing and sales infrastructure in the US.
Research and development costs
For the first quarter of 2015, Veloxis' research and development costs amounted to DKK 20.8 million compared to DKK 26.6 million during the same period in 2014. The reduction in cost is associated with the overall reduction in study activity as some studies have now been completed.
Administrative expenses
For the first quarter of 2015, Veloxis' administrative cost amounted to DKK 16.0 million compared to DKK 7.7 million during the same period in 2014. The increase in cost is mainly attributable to legal fees in connection with legal actions against the FDA.
Compensation costs
For the first quarter of 2015, a total of DKK 2.7 million was recognized as share-based compensation. The cost is included in S&M, R&D and Admin. The comparable cost for 2014 was DKK 1.8 million.
In the first quarter of 2015, a total of 221,646 warrants have been cancelled, a total of 93,416 warrants have been exercised at an exercise price of DKK 0.35, and a total of 15,091,700 warrants were granted to Executive Management at a strike price of DKK 0.94, a total of 4,748,092 warrants at a strike price of DKK 0.86 was granted to Board of Directors and a total of 8,609,143 warrants at a strike price of DKK 0.94 was granted to other employees.
On 31 March, 2015, there were a total of 128,854,009 warrants outstanding at an average strike price of DKK 0.76. Members of the Board of Directors held 5,137,676 warrants at an average strike price of DKK 0.94. Members of the Executive Management held 76,370,781 warrants at an average strike price of DKK 0.59, while other current and former employees held 47,345,552 warrants at an average strike price of DKK 1.01.
Please refer to Veloxis' latest annual report for additional details on the Company's warrant programs.
Operating loss
Veloxis' operating loss for the first quarter of 2015 was DKK 46.5 million compared to DKK 22.2 million in the corresponding period of 2014.
Financial income
During the first quarter of 2015, the Company recognized net financial income of DKK 18.0 million compared to net financial income of DKK 0.7 million in the corresponding period of 2014. The income is mainly due to unrealized currency gains following an increase in the USD / DKK currency rate during the first quarter of 2015.
Net loss
Veloxis' net loss for the first quarter of 2015 was DKK 27.0 million compared to DKK 20.0 million in the corresponding period of 2014.
Cash flow
On 31 March, 2015, the balance sheet reflects cash and cash equivalents of DKK 233.6 million compared to DKK 270.4 million on 31 December, 2014. This represents a decrease of DKK 36.8 million primarily related to the Company's operating activities for the period.
Balance sheet
On 31 March, 2015, total assets were DKK 262.7 million compared to DKK 293.7 million at the end of 2014.
Shareholders' equity equalled DKK 228.7 million on 31 March, 2015, compared to DKK 253.2 million at the end of 2014.
Significant risks and uncertainties
Executive Management's and the Board of Directors' Statement on the Interim Report
The Executive Management and the Board of Directors have considered and adopted the Interim Report for the 3 months ended 31 March 2015 of Veloxis Pharmaceuticals A/S.
The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.
We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.
Notes
1.Accounting policies
The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.
There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' annual report for 2014.
2.Research and development costs
We track research and development costs by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development costs include personnel, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities, medical affairs and other costs including cost of premises, depreciation and amortization related to research and development activities. Research and development costs are charged to operations as incurred.
